Read more

August 31, 2019
1 min read
Save

International Association for the Study of Lung Cancer announces president-elect, board members

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Heather A. Wakelee, MD
Heather A. Wakelee

Heather A. Wakelee, MD, has been chosen president-elect of International Association for the Study of Lung Cancer.

Wakelee, professor of medicine in the division of oncology at Stanford University and faculty director of the Stanford Cancer Clinical Trials Office, will serve a 2-year term.

Wakelee’s research focuses on several lung cancer subtypes, including those with EGFR , ALK , ROS1 , RET and BRAF mutations. In addition, she participates in trials that evaluate adjuvant therapy, immunotherapy and anti-angiogenesis agents.

The IASLC also announced the selection of four new members of its board of directors.

They are Andrea Bezjak, MD, FRCPC, MSc, professor in the departments of radiation oncology and health policy, management and evaluation at University of Toronto, and staff radiation oncologist at Princess Margaret Hospital; Roy S. Herbst, MD, PhD, Ensign professor of medicine, professor of pharmacology, chief of medical oncology, director of the thoracic oncology research program, and associate director for translational research at Yale Cancer Center and Yale School of Medicine; Erik Thunnissen, MD, PhD, consultant pathologist in the department of pathology at VU University Medical Center in Amsterdam; and Caicun Zhou, MD, PhD, director of the department of oncology at Shanghai Pulmonary Hospital, director of Cancer Institute of Tongji University Medical School, chairman of the oncology department at Tongji University, and head of the Chinese East-West Lung Cancer Research Group in China.

The four new board members will serve 4-year terms.

“We look forward to harnessing the talent, leadership and vision of this group of leaders in lung cancer and other thoracic malignancies,” Giorgio Scagliotti, MD, PhD, president of International Association for the Study of Lung Cancer (IASLC), said in a press release. “Having them deeply involved in strategy and leadership will undoubtedly benefit our entire organization, allowing us to expand our reach, solidify our relevance and provide our members with the world-class experience that they deserve.”

Wakelee and the four new board members will be recognized at IASLC’s World Conference on Lung Cancer, which will be held Sept. 7-10 in Barcelona, Spain.